Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.
Bryan Fitzgerald, PharmD, BCOP
Advertisement
Articles by Bryan Fitzgerald, PharmD, BCOP
Watch for alopecia, arthralgia, diarrhea, fatigue, nausea, pyrexia, rash, and vomiting, among others.
Tisotumab vedotin-tftv is used as antitumor therapy for patients with disease progression during or after chemotherapy.
Clinicians cite long-term complications and younger patients with better prognoses as reasons to pull back on oropharyngeal cancer therapy.
Addition of atezolizumab and durvalumab to chemotherapy is a win for patients with extensive-stage small cell lung cancer
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
2
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
3
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
4
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
5
